Absci Corporation

ABSI · NASDAQ

ABSI is a clinical data story before it is a revenue story: ABS-201 could validate the AI-biologics platform, but Q1 2026 still shows tiny partner revenue, heavy R&D burn, and no product sales.

Follow Add to Watchlist Ask Question

NASDAQ ABSI Coverage Bootstrap Biotechnology AI Drug Discovery Clinical-Stage Biopharma

Latest ReportMay 13, 2026Absci (ABSI): the hair-regrowth data bet hiding inside an AI drug-discovery platformView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 company reports

Add tags

Latest Thesis

Absci (ABSI): the hair-regrowth data bet hiding inside an AI drug-discovery platform

ABSI is a clinical data story before it is a revenue story: ABS-201 could validate the AI-biologics platform, but Q1 2026 still shows tiny partner revenue, heavy R&D burn, and no product sales.

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Absci Corporation(ABSI): the hair-regrowth data bet hiding inside an AI drug-discMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Absci (ABSI): the hair-regrowth data bet hiding inside an AI drug-discovery platformABSI is a clinical data story before it is a revenue story: ABS-201 could validate the AI-biologics platform, but Q1 2026 still shows tiny partner revenue, heavy R&D burn, and no product sales.NASDAQMay 13, 2026Research reportRead Slides